The Corner Drugstore: How America Is Losing Its Pharmacies and What That Means for Health, Community, and the American Promise 

by Timothy Lesaca MD (Author)  Format: Kindle Edition

Link to book is below: 

https://a.co/d/00FEzjfP 

Preface

I grew up in an era where people knew the pharmacist by first name.

I was born in 1958 and grew up in a small town where people still knew one another. We knew the pharmacist. He knew us by name, knew my father as a local doctor, and knew the ordinary map of families, illnesses, and loyalties that made a town feel like a real place rather than a loose collection of addresses. One Christmas he gave my father a gift. My father appreciated it. Looking back, I can admit there may have been some professional strategy in the gesture. Business and goodwill are not strangers. But that is not how I saw it then, and it is not chiefly how I understand it now. I saw a pharmacist who regarded himself as part of the community he served. The gift made sense because the relationship made sense. It belonged to a time when the pharmacy was woven into the life of the town.

That world should not be romanticized into innocence. Older America had cruelties of its own. Segregation was real. Poverty could be merciless. Entire groups of people were excluded from the civic warmth others remember so fondly. Still, one can reject the injustices of that past and yet say something plain. The local pharmacy once occupied a larger moral and civic place in American life than many people now realize.

It was not just a shop. It was one of the rooms where a town learned to recognize itself. A child with an ear infection went there. A mother with a worried question went there. A man embarrassed by a diagnosis went there. An older patient who had forgotten whether two bottles could be taken together went there. The pharmacist might know the doctor, the family, the street, the church, the school, the unspoken worry behind the question.

That familiarity did not solve every problem. But it made care local.

This book begins from a conviction and does not hide it. The community pharmacy should survive.

That does not mean every chain store should be preserved forever. It does not mean the past should be rebuilt exactly as it was. It does mean that the United States is treating pharmacies like retail stores while relying on them as health infrastructure. That contradiction sits at the center of the crisis. It is also the thesis of this book.

The numbers matter here. So does the history. So do the stories.

A great deal of modern pharmacy now operates inside what I will call a false economy. Price, power, and responsibility no longer sit in the same place. Pharmacy benefit managers, insurers, government programs, restrictive networks, and vertically integrated corporate structures help determine who survives, who gets steered, and who disappears. The storefront bears the labor. The decisive leverage often lives somewhere else.

The math does not work.

That sentence appears again and again in the lives of pharmacists, especially independent pharmacists, because it is true. A prescription can be filled correctly, ethically, on time, and at a financial loss. A store can do necessary work for a community and still be punished for doing it. A patient can love the local pharmacy and still be told by an insurance plan that loyalty is irrelevant, because the covered pharmacy is elsewhere and the decision is not negotiable.

When a shoe store closes, a neighborhood loses commerce. When a pharmacy closes, a neighborhood can lose one of its easiest points of contact with health care. It loses vaccines, counseling, medication reconciliation, delivery routes, emergency fills, quiet acts of noticing, and the small but meaningful dignity of being known. In some communities the pharmacy is closer than the hospital and more reachable than the doctor's office. In poor neighborhoods and rural counties, that fact is not incidental. It is everything.

I have tried to write this draft with seriousness, but not coldness. The history matters because the present should not be allowed to pretend it was inevitable. The economics matter because sentiment without arithmetic is helpless. The human stories matter because systems only become morally legible when they pass through individual lives. This draft reflects the state of the subject through April 2026. Facts will keep moving. The deeper question will not.

What kind of country closes the local pharmacy and calls that efficiency?

Introduction

In North Lawndale on Chicago's West Side, pharmacist Edwin Muldrow has described buying an Advair inhaler for about six hundred dollars and being reimbursed roughly four hundred. In Texas, pharmacists have described losing money on insulin before rent, payroll, electricity, or insurance are even counted. Those are not bookkeeping errors. They are glimpses of the business model.

This is where the story starts.

A pharmacy can do the work. It can fill the prescription, counsel the patient, keep the refrigerator running, train the staff, follow the regulations, file the claim, and still lose money on the transaction. It can be needed by the neighborhood and punished by the system at the same time. Once that reality is understood, much of what looks baffling in American pharmacy stops being baffling at all.

The United States is treating pharmacies like retail stores while relying on them as health infrastructure.

That is the central argument of this book. I repeat it here because it deserves to be stated plainly. Pharmacies are expected to be nearby, reliable, clinically literate, open, staffed, compliant, digitally connected, and ready for emergencies. They are expected to vaccinate, counsel, reconcile medications, answer insurance questions, hold controlled substances safely, manage cold chain inventory, and increasingly function as low-threshold health access points. Yet they are still paid, governed, and judged as though they were ordinary merchants with a few extra headaches in the back room.

During COVID, the contradiction became impossible to ignore. The pharmacy, half hidden for years behind greeting cards and shampoo aisles, suddenly stepped into full view. Clinics were overwhelmed. Hospitals were strained. Primary care offices were backed up. The local pharmacy remained open. People went there for tests, vaccines, explanations, and reassurance. The Federal Retail Pharmacy Program grew to more than 41,000 locations and delivered more than 307 million doses. Retail pharmacy partners administered 67.7 percent of all bivalent COVID vaccine doses in the United States between September 2022 and September 2023. In practical terms, that meant the country leaned on the local pharmacy as if it were a civic utility. It was. The country just never paid for it that way.

Then the emergency receded and the old arithmetic returned. Rite Aid filed for bankruptcy again in May 2025 and began a rapid sale of prescription files and store assets. Walgreens agreed to go private under Sycamore in March 2025 and later changed leadership as the new owners moved to restructure the chain. CVS completed the closure of about 900 stores from 2022 through 2024 and planned roughly 270 more in 2025. The civic hero of the emergency became, almost at once, a distressed category of American retail.

That whiplash revealed a national misunderstanding.

People assumed the crowds must have meant the stores were thriving. They were not. Volume is not the same thing as viability. A pharmacy can be busy all day and financially weaker at closing than it was at opening. Someone has to absorb the loss. Increasingly that someone has been the pharmacy itself, or the owner, or the staff, or the community that loses the store when the numbers no longer hold.

This is the distortion in practice.

In ordinary commerce, price and payment are easier to see. In modern pharmacy, price authority has drifted away from the counter. The patient usually pays only part of the price, or pays a copay so detached from the actual transaction that it reveals almost nothing. The pharmacist often does not know the true reimbursement until the claim adjudicates. The real power sits with insurers, PBMs, employer plans, government programs, and network rules. The place that appears to be making the sale may be the least powerful party in the exchange.

And yet economics alone cannot explain the full story. Pharmacy has a long memory. It is older than the drugstore, older than the nation, older than the neat categories by which modern medicine now explains itself. For centuries pharmacists, apothecaries, and druggists stood between raw medicinal substances and actual human use. The jars changed. The formulas changed. The duty did not. Someone still had to know what was safe, what was stable, what interacted, what spoiled, what healed, and what might kill.

In America that duty took on a particular civic shape. The pharmacist was not merely a dispenser. He or she was often a neighborhood witness, a translator of medicine into daily life, a small business owner, and one of the few health professionals people could approach without an appointment. That older order had serious defects. One should not varnish over segregation, exclusion, or untreated poverty. But there was something real in the local pharmacy's place within ordinary community life, and something costly in its disappearance.

This book moves from deep history to present crisis.

It begins before the drugstore, with the old apothecary problem of sorting useful remedies from dangerous ones. It follows the American pharmacy through Main Street, industrial drug manufacturing, chain expansion, and the rise of the modern reimbursement maze. It lingers over the pandemic, because COVID briefly revealed what the country had always had and never fully valued. It then turns to closures, pharmacy deserts, workforce strain, legal fights over PBMs, and the uneasy future now coming into view.

It also takes a side.

I do not believe the destruction of the community pharmacy is an acceptable price of modernization. Some innovation is genuinely helpful. Home delivery can be a gift. Digital prescribing is often better than paper. Dose packaging helps many patients. Mail order can work well for stable maintenance drugs. None of that requires us to accept a future in which the physical pharmacy disappears from neighborhoods that are already medically fragile and economically strained.

There is a difference between innovation and abandonment.

The argument that follows is historical, economic, moral, and practical all at once. It asks what we built, what we forgot, what we asked the pharmacy to become, and why the math now points toward disappearance just when the need for local access has become harder to deny. It is about money, certainly. It is also about presence, because medicine without nearby presence becomes more brittle than a healthy society should ever tolerate.

Chapter One: Before the Counter

Before there was a pharmacy there was a risk.

People were swallowing, brewing, grinding, applying, burning, and storing substances they did not fully understand. Some of those substances healed. Some did nothing. Some poisoned. The earliest history of pharmacy is not really the history of a store. It is the history of an old human problem. Remedies are powerful. Someone has to know what is in the jar.

Ancient Egypt already understood something like that duty. The Ebers Papyrus, compiled around 1500 BC, recorded hundreds of remedies and medicinal preparations. Greek and Roman medicine inherited and expanded similar traditions. Dioscorides's De materia medica, written in the first century, cataloged plants, minerals, and animal substances with a practical seriousness that kept the work alive for more than a thousand years. Across these traditions, one idea kept reappearing. It was not enough to find a substance. One had to identify it, prepare it, measure it, and pass along trustworthy knowledge about what it did.

That emphasis on trustworthy preparation links the ancient bench to the modern counter. Pharmacy, before it was a retail business, was an answer to uncertainty. Remedies can heal, fail, spoil, vary, or kill. Someone must know the difference between useful and harmful, between crude and refined, between a dose and an overdose. The oldest history of pharmacy is therefore a history of discernment.

The medieval Islamic world pushed that discernment toward a recognizable profession. Historians often point to Baghdad in the eighth century, around 754, as the site of the first true apothecary shop. That mattered because it signaled a society sophisticated enough to separate diagnosis from preparation and dispensing. Public pharmacies later appeared in Europe in the twelfth century. Guilds, municipal rules, and professional distinctions slowly followed. The separation was never perfect. Monks, herbalists, physicians, merchants, barber surgeons, and outright charlatans all crowded the same terrain. Still, the long trend favored differentiation.

By the seventeenth century, apothecaries in parts of Europe had become durable social figures. They were licensed, inspected, and expected to know the practical science of medicines. That development mattered for a reason modern readers can still feel. Medicine depends on trust, but trust is not created by goodwill alone. It depends on standardization. The right herb taken from the wrong plant, the right powder weighed on the wrong scale, the right preparation left too long in heat or moisture, each can turn treatment into a false promise.

Even the old sensory image of the apothecary tells the story. Mortars, pestles, drawers, tinctures, labeled jars, scales, ledgers. These are not quaint decorations. They are material answers to uncertainty. They say that sickness has met order. Someone has sorted, named, stored, measured, and kept watch.

The modern bottle with its bar code and lot number looks different. The underlying fear is the same.

By the time pharmacy crossed the Atlantic into colonial America, it carried this old inheritance with it. The setting would change. The duty would not. Someone would still stand between the abstract possibility of treatment and the concrete act of placing a medicine safely into a human hand.

That old duty is what made the American pharmacy possible. It also explains why the loss of the local pharmacy feels like more than retail decline. The story, from here on out, becomes less ancient and more recognizably American.

Chapter Two: Main Street Medicine

America did not begin with the chain drugstore.

It began with the apothecary, the druggist, the mixed shop, and the general merchant who gradually became something more specialized. Colonial America had few standalone pharmacies in the modern sense. Medicines were imported, compounded locally, sold in hybrid shops, or prepared by physicians themselves. In a thinner society with greater distances and fewer institutions, lines between professions stayed elastic.

Even so, the separation between prescribing and dispensing began to matter early. Benjamin Franklin made a small but telling choice when he appointed an apothecary to Pennsylvania Hospital. That decision helped formalize a distinction that would shape American health care for generations. The person who diagnosed disease was not necessarily the person who prepared and controlled the medicinal stock.

The profession matured quickly in the early republic. In 1820 the United States Pharmacopeia was founded to establish standards for the strength and purity of medicines. In 1821 the Philadelphia College of Pharmacy became the first college of pharmacy in the United States. These were not decorative milestones. They marked an effort to move the handling of medicines out of apprenticeship alone and into more systematic public knowledge. To standardize a drug is to say that a patient in one town deserves the same confidence in a remedy as a patient in another.

Nineteenth century American pharmacy was never pure. It was an age of compounding and professionalism, but also of patent medicines, extravagant claims, dubious tonics, and a porous boundary between science and salesmanship. The druggist's world included respectable preparations, household remedies, and commercial hype in the same room. The pharmacy helped medicine become more trustworthy. It also sat close enough to commerce to remind everyone how easily trust can be exploited.

That tension is part of what made the American pharmacy such a distinctive civic institution. The best pharmacists did not simply sell. They interpreted. They knew which doctor wrote in a hurried hand, which widow needed an explanation twice, which child resisted bitter syrup, which household had more pride than money, which family member ought to be told quietly that a dosage looked wrong.

As the nineteenth century gave way to the twentieth, the American drugstore acquired a social identity that reached far beyond the prescription. It became one of Main Street's stable rooms. Soda fountains appeared. Toiletries, stationery, shaving supplies, cosmetics, and small household goods joined the medicinal trade. In many towns the pharmacy was partly health establishment and partly everyday mercantile stop, a place where prescriptions were filled and neighborhood life passed by in miniature.

This mixed character made the pharmacy unusually intimate. The grocer knew what you ate. The pharmacist often knew what you feared. Doctors and pharmacists knew one another personally in many communities. They corrected one another, argued, cooperated, and moved through the same civic circles. The pharmacist was often a small proprietor rooted in the same streets as the patients he served. He bought local ads, supported school events, attended church, joined service clubs, and lived with the practical consequences of local reputation.

That older arrangement made entrepreneurship in pharmacy feel plausible in a specifically American way. A trained pharmacist, including one from an immigrant family, could imagine opening a store, building trust, and carving out a livelihood through skill, discipline, and local standing. The barriers were real, especially for those blocked by race, class, or gender. Still, the model existed. The community pharmacy belonged to a broader promise that professional independence and local ownership were not fantasies.

One should not sentimentalize this world too cheaply. The old neighborhood was not a universal refuge. Many communities were segregated. Many patients could not afford what they needed. Women and minority professionals met ceilings that were often brutal and routine. A society can be locally rooted and profoundly unjust at the same time.

Still, something valuable lived in the old pharmacy's place within ordinary civic life. It was one of the few institutions where commerce and care met without fully cancelling each other out. People entered because they needed something specific. They often left with more than a product. They left with explanation, warning, reassurance, or recognition.

That trust would survive astonishing changes in medicine. Industrial drug manufacturing would strip much of the old compounding work from the pharmacist's hands. Regulation would widen. Insurance would spread. Computers would arrive. Chains would rise. Yet even after the soda fountain vanished and the labels came preprinted, millions of Americans still walked into a pharmacy expecting that the person behind the counter knew the difference between a transaction and a responsibility.

Scale would test that expectation. It would also monetize it.

Chapter Three: How the Drugstore Became Big Business

Big business did not arrive in pharmacy as pure villainy. It arrived as convenience, scale, standardization, and modernity. The twentieth century turned the pharmacist from a recognizably local professional into the steward of a mass retail form, and for a long time Americans experienced that transformation as progress.

That perception was understandable. Factory-made drugs were often cleaner, stronger, more consistent, and more precisely dosed than the compounded medicines that came before them. Regulation improved. Packaging improved. Supply chains improved. The old druggist became less a maker of medicines and more an expert custodian of medicines. What changed was not the need for skill. It was the scale at which skill had to operate.

Industrial pharmaceutical manufacturing, especially after World War II, reduced the centrality of extemporaneous compounding. More medicines arrived in standardized, factory-produced forms. That shift was an advance. It delivered cleaner manufacturing, more precise dosing, broader access, and drugs of a power and consistency earlier apothecaries could scarcely have imagined. It also meant that the pharmacist became less a maker of medicines and more an expert custodian of medicines, responsible for storage, verification, dispensing, counseling, interaction checking, and increasingly complex documentation.

Federal regulation helped build that new trust. The 1906 Food and Drugs Act was a watershed in the policing of adulteration and misbranding. The 1938 Food, Drug, and Cosmetic Act, shaped by tragedy and public outrage, further strengthened the expectation that medicines sold in the United States would meet standards backed by law, not just reputation. Pharmacists operated downstream from those protections, but the public often experienced the assurance through them. The pharmacy counter became the local face of a national system of standards.

At the same time, scale was rewriting the business. Chain drugstores refined the idea that had been latent in the nineteenth-century druggist. A store could be both a health outlet and a broader convenience merchant. Charles R. Walgreen's early stores in Chicago helped popularize a cleaner, more standardized, more aggressively merchandised version of the drugstore. Other regional and national players followed. Over time, the store became less idiosyncratic, more replicable, and more closely integrated with mass retail habits.

By the late twentieth century, the American pharmacy had become a hybrid institution. The prescription counter in the back drove traffic. The front of the store sold everything else. Greeting cards, candy, cosmetics, batteries, detergent, seasonal items, magazines, and small emergency necessities formed part of the economic ecology. The pharmacy was not merely a dispenser. It was an anchor for daily convenience.

For years that hybrid made sense. Prescriptions pulled people into the building. Front-end purchases helped cover the fixed costs of rent, lighting, security, refrigeration, wages, and inventory. The margins on the bottle might be thin. The basket at the register could still work in the store's favor. A community pharmacy or chain branch could therefore survive partly because it was a health service and partly because it was a general retail stop.

Insurance helped enlarge volume, but it also began shifting power away from the storefront. As employer-sponsored coverage expanded, as government programs matured, and as pharmacy benefit managers rose inside the claims machinery, the pharmacist's relation to price grew more mediated. Volume increased. Autonomy thinned. The drugstore looked busy, often legitimately busy, while the terms of its survival were moving out of the building.

Chains responded in the way large firms often do when a model still works well enough to invite overconfidence. They expanded. They bought locations, clustered stores, and pursued ubiquity. In 2015 CVS acquired Target's pharmacy business, taking over 1,672 in-store pharmacies. Walgreens acquired 1,932 Rite Aid stores in 2018 after antitrust scrutiny narrowed the original deal. Saturation became a kind of strategy. There were neighborhoods, especially in major cities, where drugstores multiplied with a confidence that felt permanent.

It was not permanent. Much of the visible contraction of the 2020s was already implicit in that earlier exuberance. A system built for dense physical coverage, robust front-store margins, and durable prescription reimbursement was always going to look fragile once online retail expanded, payer pressure increased, and every square foot had to justify itself more ruthlessly. In hindsight, parts of the market were not merely competitive. They were overbuilt.

Even before the pandemic, the old drugstore formula had begun to wobble. The shelves remained. The foot traffic remained. The store still looked familiar. Underneath, the supports were shifting. A clinical necessity was riding on a retail platform whose economics had started to give way. The building was still standing. The foundation was not as sound as it looked.

The next problem was stranger still. Once the store stopped controlling the basic terms of the sale, the crisis ceased to be a normal business story and became something more distorted.

Chapter Four: The False Economy

This is where the system breaks. In most commerce, the seller sets the price and the buyer decides whether to pay it. In pharmacy, that picture falls apart. The buyer usually does not pay the full price. The seller usually does not control the effective price. The decisive terms are set by intermediaries who may never meet the patient face to face.

The seller does not really set the price. The buyer does not really pay the price. That is the false economy at the heart of the pharmacy crisis.

It is false not because the money is unreal, but because the visible transaction misleads almost everyone involved. A patient hands over an insurance card and pays a copay. The pharmacist scans, submits, waits, and learns what the claim will yield. The amount paid by the plan may bear little obvious relation to the cost the pharmacy incurred to buy the drug.

The patient often assumes the store is in command because the store is where the exchange happens. The store often is not in command at all.

Pharmacy benefit managers sit near the center of this system. They began as administrators of prescription claims and benefit design. Over time they became something much more powerful, negotiators of formularies and rebates, designers of pharmacy networks, setters of reimbursement terms, and gatekeepers of where many patients may fill prescriptions at the most favorable price. According to the Federal Trade Commission, the three largest PBMs, CVS Caremark, Express Scripts, and OptumRx, now manage 79 percent of prescription drug claims for roughly 270 million people.

Concentration alone would be enough to matter. Vertical integration makes it more consequential. The largest PBMs are not simply middlemen floating above the market. They are tied to insurers, specialty pharmacies, mail-order platforms, clinics, and in one case the largest retail chain itself. The FTC has found that these arrangements can steer revenue toward affiliated pharmacies, especially in the specialty sector where margins are richer and the patient is even further from transparent pricing.

To see why this matters, one must resist the comforting simplification that PBMs merely negotiate savings. They do negotiate. They also decide networks. A patient who thinks he is choosing a pharmacy may discover that his plan has already chosen for him. Sometimes the pressure is subtle. A preferred pharmacy carries lower cost sharing. A nonpreferred pharmacy costs more. Sometimes the constraint is much harder. A local independent pharmacy is simply out of network, or a specialty drug must be routed through an affiliated channel.

This is the point at which the familiar language of consumer choice starts sounding theatrical. A patient may like the local pharmacist, trust the local pharmacist, or live closer to the local pharmacist. None of that helps if the plan design says otherwise. A physician may wish to support a community pharmacy and still find that the patient's economic reality forces the prescription somewhere else. In that sense the system does not merely shape competition. It scripts it.

To see the distortion in slow motion, imagine a single prescription. A pharmacy buys an inhaler for six hundred dollars. The patient arrives with an insurance card and pays a thirty-dollar copay. The claim is adjudicated in seconds. The plan and its PBM return four hundred dollars in reimbursement. To the patient, the transaction looks complete. The store has received four hundred thirty dollars altogether, the patient has received the inhaler, and everyone goes home. But the pharmacy paid six hundred dollars to acquire the drug. Before rent, wages, software, refrigeration, label, vial, counseling time, and card-processing fees, the store is already one hundred seventy dollars underwater. If a later reconciliation, fee, or clawback takes more, the loss deepens. That is how a prescription can look fully paid on the surface while remaining financially destructive underneath.

The distortions become sharpest when reimbursement falls below acquisition cost. That sounds impossible until one remembers how little of the transaction is actually governed by the pharmacy. Reported examples from around the country show the arithmetic. In Texas, independent pharmacist Dana Tilton described filling an insulin prescription that cost $414.21 to acquire and generated reimbursement of $403.16. Before labor, rent, label, vial, software, utilities, or any counseling time, the prescription was already $11.05 underwater.

In Chicago, Edwin Muldrow of Del-Kar Pharmacy said an Advair inhaler that cost his store around $600 might be reimbursed at only $400.

That is not a margin problem. It is a negative sale.

The old pharmacy model could sometimes absorb thin margins because the front of the store helped subsidize the back. It cannot reliably absorb repeated negative transactions. The math is merciless. If a pharmacy loses only $5 on twenty prescriptions a day, that is $100 a day, about $36,500 a year, before one counts the salary of the pharmacist, the technicians, the lease, the refrigeration, the software, the insurance, and the ever-growing compliance burden.

If a handful of specialty or brand claims lose far more, ordinary prescription volume cannot make up the difference. Volume only accelerates the loss.

Dispensing fees, meant to compensate pharmacies for the professional and operational work of filling a prescription, no longer reliably close the gap. Muldrow told reporters that what once might have been a three-dollar dispensing fee decades ago can now fall to pennies. One begins to understand why some owners describe their businesses as moving products for others while holding the risk themselves.

The chains know this too. Their corporate filings read like dry legal prose, but the message is clear. CVS states that substantially all of its pharmacy revenues come through PBMs, managed care organizations, government programs, employers, and other third-party payors. Walgreens says the substantial majority of the prescriptions it fills are reimbursed by third-party payors and warns that reimbursement pressure from PBMs, governments, and commercial insurers continues to intensify.

Walgreens also notes that more of its business has shifted toward lower-reimbursement categories such as 90-day retail prescriptions and Medicare Part D volume.

This is one reason the popular story of chains versus independents is too simple. Independent pharmacies are often more exposed and less able to cross-subsidize losses. Yet the chains themselves are also caught in a reimbursement machine they do not fully control. The difference is that some of the chains helped build the machine that now constrains them. CVS is not merely squeezed by PBMs. It owns one of the dominant PBMs. That is not a footnote. It is one of the deepest contradictions in the modern pharmacy economy. The storefront may be under strain while the enterprise above it still profits through benefit design, specialty steerage, or affiliated dispensing.

The chains are therefore both victims and architects of the system. That tension deserves to be stated plainly.

That elsewhere increasingly means specialty and affiliated channels. The FTC's second interim report on PBMs found that the affiliated pharmacies of the three largest PBMs generated more than $7.3 billion in dispensing revenue above NADAC, the National Average Drug Acquisition Cost benchmark, on 51 specialty generic drugs between 2017 and 2022. The FTC also found that PBM-affiliated pharmacies have come to account for nearly 70 percent of specialty drug revenue. Profit did not disappear from pharmacy. It moved.

That migration helps explain why the neighborhood store feels perpetually squeezed even while Americans spend enormous sums on medicines. The brightly lit retail counter holds the labor, the patient confusion, the insurance phone calls, the refrigeration, the shrinkage, the staffing shortage, and the risk of being the last accessible health professional in a struggling zip code. The higher-margin business increasingly resides in mail order, specialty fulfillment, vertically integrated benefit design, or corporate structures the patient never sees.

Congress did finally move, at least a little, in early 2026. The Consolidated Appropriations Act of 2026 included PBM-related reforms aimed at transparency and delinking certain compensation in Medicare Part D from drug prices and rebates. Those changes matter. They may curb some of the most abusive spread-pricing incentives. They do not, by themselves, rebuild the physical economics of the neighborhood pharmacy. You can regulate one abuse and still leave the storefront impossible to run.

The distortion remains. The local pharmacist performs the public-facing work while the decisive power lives elsewhere. Until that is understood, nearly every discussion of pharmacy access will remain one level too shallow.

If the United States were honest about this, it would stop pretending the pharmacy is just another retailer. A store that must remain ready for illness, urgency, counseling, refrigeration, compliance, controlled substances, and vaccine delivery is not functioning as an ordinary merchant. It is functioning as health infrastructure under retail accounting.

Chapter Five: The Brief Apotheosis of the Pharmacy

For a brief moment, the country remembered what the pharmacy was for. The long-term economics were already fraying, but the pandemic covered that weakness with urgency and public purpose. In a crisis, institutions reveal themselves by what they can still do when other systems are faltering. The community pharmacy turned out to be one of the most scalable, local, and trusted delivery systems in American health care.

This was not an abstraction. It was feet on tile. It was people lining up between the greeting cards and the cough medicine. It was technicians managing paperwork, pharmacists drawing doses, freezers humming, phones ringing, and exhausted staff members explaining the same eligibility rule or booster interval for the fiftieth time that day. It was public health conducted in the language of ordinary neighborhoods.

It was public health with fluorescent lights, paper forms, harried phone calls, and people who knew the neighborhood. It was not glamorous, but it was indispensable.

The numbers now make that moment undeniable. Retail pharmacy partners administered 67.7 percent of all bivalent COVID vaccine doses between September 2022 and September 2023. In urban areas they delivered more than four out of five of those doses. By early 2024 pharmacies were providing more than seventy percent of boosters nationwide. CVS alone reported administering more than 59 million COVID vaccines and more than 32 million tests in 2021.

The country relied on this capacity because pharmacies had what many other institutions lacked. They had location density. They had extended hours. They had refrigeration. They had trained professionals already accustomed to handling medication safety, documentation, and patient questions. Most of all, they had social familiarity. A person uneasy about entering a hospital or unable to secure a primary care appointment could still walk into a pharmacy.

There was dignity in that. Pharmacies were not merely filling a gap. They were proving something about the architecture of care. They showed that public health does not always arrive in grand buildings. Sometimes it arrives in strip centers and on corners, in places that look too commercial to be understood as essential until the emergency strips away the illusion.

Yet the pandemic surge also deepened a dangerous misunderstanding. Crowds are easy to mistake for profit. Visibility is easy to mistake for stability. The public saw lines, vaccine tents, and extra responsibilities, then assumed the pharmacy business must finally be thriving. The reality was harsher. The pandemic created a temporary overlay of activity and reimbursement atop a model that had not been structurally repaired. Once testing demand faded and the extraordinary vaccine volumes subsided, the underlying stresses returned with very little mercy.

CVS's own later results tell the story. The company could boast of pandemic vaccination and testing volumes in 2021, then by 2024 return to reporting continuing reimbursement pressure, lower front-store sales, and lower contribution from COVID test kits as reasons operating income in the retail segment had fallen. The boom was real. It was not a cure.

The labor toll was real as well. Pharmacists and technicians who had long complained about staffing strain, metrics pressure, and unsafe workloads now found themselves carrying additional public obligations in stores that were already stretched. Walkouts at CVS and Walgreens in 2023 were not only a labor dispute. They were a sign that the pharmacy's elevation into quasi-public infrastructure had not been matched by equivalent protection of the people performing the work.

One can argue about whether government forced this role onto pharmacies or whether pharmacies, especially the chains, stepped forward because the moment offered both duty and opportunity. The honest answer is probably both. The federal government clearly relied on the retail network as a mass vaccination platform. The chains clearly embraced the visibility and traffic. The independent pharmacies and small community stores did what local institutions often do in emergencies. They showed up because the people in front of them were their people.

That is why the later retrenchment felt like a civic insult as much as a business adjustment. Pharmacies had been treated, for a season, as indispensable public rooms. Once the crisis ebbed, they were returned to a reimbursement order that still expected them to survive like merchants selling ordinary goods.

The applause was real, but it did not fix the math.

Chapter Six: The Retreat

The applause faded faster than the debt. What followed COVID was not a sudden collapse from health into sickness. It was the unveiling of problems that had been gathering for years. A 2025 study in JAMA Health Forum described the arc cleanly: chain pharmacies posted net gains from 2010 to 2015, then net losses from 2016 to 2023. The retreat of the present decade is therefore partly a crisis and partly an unwind.

CVS's own numbers reveal how the old retail formula has frayed. After announcing a strategic review in 2021, the company closed about 900 stores between 2022 and 2024 and scheduled another 271 closures for 2025. Front-store same-store sales fell 2.1 percent in 2024. Even more telling, front-store and other revenue shrank to 19.1 percent of the Pharmacy and Consumer Wellness segment's sales, down from 23.1 percent in 2022. That is the old subsidy weakening in plain view.

This matters because it changes the tone of the story. Some closures really are corrections of overbuilding. Others are something harsher. They are the loss of the last nearby counter in places that were never overbuilt at all.

The front of the store is contributing less to a building whose back end is already under reimbursement pressure.

Walgreens has lived the same broad story in a different register. In late 2024 it said it would close about 1,200 stores over three years, including roughly 500 in fiscal 2025. Its filings describe ongoing reimbursement pressure and a mix shift toward lower-margin prescriptions. The company also acknowledges that it does not participate in all preferred Medicare Part D networks, an admission that tells you how much strategic power now resides in benefit design rather than street-level convenience.

Walgreens entered private ownership in 2025 with the kind of burdened balance sheet and uncertain footprint that often invite more aggressive rationalization, not less.

The logic of private equity has not promised relief. Reuters reported in February 2026 that Walgreens was cutting more than six hundred jobs after the Sycamore buyout, a reminder that financial engineering rarely rescues storefront care simply by believing in it harder.

Rite Aid's second Chapter 11 filing in May 2025 made the consequences more visible still. In the months that followed, the company sold prescription files, closed stores, and left communities to absorb the inconvenience and risk of transfer. One reason such closures feel uniquely disruptive is that prescriptions are not like ordinary retail loyalty. A closed pharmacy forces an administrative migration of therapy itself. Bottles, histories, refill patterns, counseling relationships, delivery routines, and the simple habit of where one goes when sick all have to be uprooted.

The chains attempted various escapes from this pressure. Some stores were redesigned into smaller formats. Others reduced general merchandise. Still others tried to become more explicitly clinical. Walgreens bet heavily on VillageMD and adjacent primary care. CVS pursued HealthHUBs, MinuteClinic expansion, and a broader integration strategy. The ambition was understandable. If the old combination of pills and detergent no longer justified the rent, perhaps the store could become a mini health center.

In practice, that strategy often overreached. Walgreens took a multibillion-dollar impairment on VillageMD in 2024 and closed more than 160 clinic sites. CVS later reduced the pace of new primary care expansion and reconsidered parts of its care delivery footprint. Even where such clinics improved access, they often struggled with continuity, turnover, or simply the mismatch between episodic retail traffic and the relational demands of longitudinal care. A walk-in sore throat is one thing. Ongoing primary care is another.

None of this means physical pharmacy was doomed everywhere in the same way. Geography matters. There are still urban corridors where the old chain density was so excessive that some retrenchment looks less like abandonment than correction. New York is the classic example. Many residents can remember corners crowded with Duane Reades, Walgreens, and CVS locations at intervals that felt almost comic. A vacancy in such areas does not automatically create a pharmacy desert.

Research on pharmacy deserts in New York City, Los Angeles, Chicago, and Houston makes the point with useful precision. Between 2015 and 2020, the share of neighborhoods classified as pharmacy deserts actually declined in New York, from 1.6 percent to 0.9 percent, even as deserts remained more common in Black and Latino neighborhoods across all four cities. In Chicago and Houston, the problem worsened. The lesson is simple. A shuttered midtown drugstore and the loss of the last nearby pharmacy in a poor neighborhood are not the same event.

Competition from outside the classic drugstore model has compounded the squeeze. Walmart, supermarket pharmacies, discount chains, mail-order services, and Amazon have all eroded the old assumption that the corner drugstore is the fastest or easiest answer. Amazon Pharmacy announced in February 2026 that it would expand same-day prescription delivery to nearly 4,500 cities and towns by the end of the year. For many stable chronic prescriptions, that convenience is genuine. For the neighborhood store trying to keep fixed costs covered, it is one more leak in the hull.

By now the picture is clear. The postwar American drugstore was built on a combination of local convenience, front-store impulse purchasing, abundant physical footprint, and reimbursement levels that, while often imperfect, were not yet systematically crushing. That combination no longer holds. The store has not ceased to matter. It has ceased to be supported by the assumptions that once made it seem immortal.

And when the retreat reaches a poor neighborhood or a rural town, it stops being a story about fewer choices and becomes a story about no nearby pharmacy at all.

Chapter Seven: Pharmacy Deserts

A child spikes a fever at nine o'clock. An elderly man runs out of anticoagulant on a Friday evening. A woman leaves the hospital with antibiotics that need to be started before the next dose window closes. A town loses its last pharmacy and the next nearest one is thirty miles away. Suddenly the phrase pharmacy desert stops sounding academic.

Recent research suggests the scale of the problem is already enormous. A 2025 study in JAMA Network Open found that 57.1 million Americans, 17.7 percent of the population, lived in pharmacy deserts. Another 28.9 million relied on a single pharmacy for access. Put together, that means more than one in four Americans either lived in a desert already or stood one closure away from one.

The closures behind those deserts are not anecdotal. A 2024 analysis in Health Affairs found that of 88,930 retail pharmacies operating between 2010 and 2020, 29.4 percent had closed by 2021. That is more than 26,000 pharmacies gone in just over a decade. The closures accelerated in the later years of that period, enough to produce the first net decline in retail pharmacies after decades of expansion.

Where the closures occur matters as much as how many there are. The risk of closure has been higher in predominantly Black and Latino neighborhoods than in White neighborhoods. Independent pharmacies have been more than twice as likely to close as chain pharmacies. Small rural communities are especially exposed because redundancy is scarce. The local pharmacy there is not one option among many. It is often the option.

The disparities can be made painfully concrete. USC researchers found that in Chicago only 1 percent of white neighborhoods were pharmacy deserts, compared with 33 percent of Black neighborhoods on the South Side. In a later Chicago analysis, researchers found that only 1 percent of White neighborhoods were pharmacy deserts compared with 42 percent of Black neighborhoods. That is not random inconvenience. It is patterned withdrawal.

This is why pharmacy deserts raise a sharper moral question than ordinary retail decline. If a neighborhood loses a big-box electronics store, life goes on with inconvenience and some economic cost. If a neighborhood loses its pharmacy, health care itself becomes harder to reach. Pharmacies provide not only pills. They provide immunizations, counseling, point-of-care testing, medication reconciliation, adherence reminders, supplies, and immediate judgment about whether a problem belongs at home, at urgent care, or in an emergency room.

In many communities, especially low-income communities, the pharmacy is physically closer than the hospital and more practically available than the doctor. That fact should change the way the subject is argued. A pharmacy is not a luxury retail presence that communities happen to like. It is a distributed access point in the health system. Closing it in the name of efficiency can amount to withdrawing care from the map.

This is why the term medical redlining, while severe, is not merely rhetorical. Traditional redlining denied credit and investment to neighborhoods judged undesirable or unprofitable. Pharmacy withdrawal is not identical. But when low-reimbursement neighborhoods repeatedly lose essential drug access while affluent areas retain options, the moral resemblance is hard to miss.

Because the burden falls unevenly, the question also takes on a civil-rights character. Researchers studying major U.S. cities found that pharmacy deserts remained persistently more common in Black and Latino neighborhoods even where overall citywide access appeared acceptable. This is the geography of health inequality translated into storefronts. When firms use payer mix, reimbursement potential, and algorithmic forecasting to decide which locations are worth keeping, they are not merely optimizing. They are selecting which communities will carry more friction in getting medicine.

Texas offers one vivid illustration. Reporting in 2026 found that more than 4.3 million Texans lived in pharmacy deserts and that the state pharmacy association was watching about one pharmacy close each week. In some parts of the state, the issue is compounded by distance and transportation. In urban neighborhoods, it is compounded by poverty and chronic disease. Different geographies, same consequence, longer travel, more delay, less counseling, greater chance that a prescription simply goes unfilled.

There is also a quieter loss that statistics capture poorly. The pharmacy often functions as a low-threshold checkpoint in people's lives. A pharmacist notices swelling, confusion, repeated early refills, duplicative therapy, a child whose inhaler technique is wrong, an older adult who has stopped taking something because the bottle ran out and no one explained the refill. These are small interventions individually. In aggregate they are part of what keeps a fragmented health system from becoming even more dangerous.

A desert therefore does not merely reduce consumer convenience. It removes the easiest available encounter with medication expertise. It lengthens the distance between prescription and possession, and between possession and understanding. For a population with rising chronic disease burden, aging demographics, and vast inequalities in transportation and primary care access, that is not a minor civic injury.

Policy discussions sometimes treat these closures as regrettable but natural outcomes of market adjustment. That language understates the stakes. Markets are not weather. If an access point essential to public health vanishes because the payment structure makes it irrational to remain, the disappearance should not be shrugged off as though no collective choice were involved. We built the rules. We can build others.

The numbers are national. The losses are intimate. To see what they feel like, one has to go back to the counter and the people still standing behind it.

Chapter Eight: The Human Ledger

The numbers are necessary, but numbers alone can anesthetize judgment. Twenty-six thousand closures. Fifty-seven million people in pharmacy deserts. Seventy-nine percent of claims controlled by three PBMs. Each figure clarifies. None of them bleeds. To understand what the crisis means, one has to return to the level of the counter, the invoice, and the neighborhood.

Consider Del-Kar Pharmacy in North Lawndale on Chicago's West Side. The store was opened by Edwin Muldrow's father in the 1960s. That detail matters because it tells you what kind of institution this is. It is not only a storefront but an inheritance, a family business embedded in a historically Black neighborhood that has had to withstand disinvestment from many directions. Muldrow told reporters that an Advair inhaler might cost his pharmacy $600 to acquire and be reimbursed at only $400.

He also said dispensing fees that once ran around three dollars a prescription decades ago can now fall to as little as ten cents. He survives in part because he owns the building.

That last fact is a hidden chapter in many independent pharmacy stories. Real estate sometimes functions as the final buffer. A family that owns its building can endure shocks a tenant cannot. Yet even ownership has limits. When reimbursement turns negative, property is not a business model. It is a temporary shield. North Lawndale also lost a nearby Walgreens, which means the surviving independent store becomes both more essential to the neighborhood and more financially burdened by the very dynamics that closed the chain site.

Now shift to Basin, Wyoming. Craig Jones, an independent pharmacist there, told the Associated Press in 2024 that about a quarter of the prescriptions he filled were reimbursed below acquisition cost. By mid-May he said the store had already lost $30,000 on those transactions. This is the kind of arithmetic people outside pharmacy rarely confront. A quarter of the work can be honest labor and still be financially destructive. One does not need incompetence or scandal to get a business in trouble.

One needs enough transactions that look viable from the street and fail in the back office.

Or consider the Texas Panhandle, where pharmacist Crystal McEntire was profiled in 2026 living what sounded almost like two economic lives. She and her family run cattle, and that separate business helps keep the pharmacy operation afloat. Another Texas pharmacist, Dana Tilton, described losing money on insulin before any operating costs were counted. These are not romantic frontier tales.

They are evidence that in some places the pharmacy survives only because another line of business, another family asset, or another piece of luck subsidizes what should be a viable health service on its own.

What emerges from these stories is not merely hardship. It is inversion. The pharmacy is doing work the community plainly needs while relying on unrelated cushions to survive it. A ranch props up the drugstore. A building inherited from one's parents absorbs the shock. A spouse's income, a small town's loyalty, or the owner's unpaid hours become invisible subsidies. Public need is being met by private sacrifice that the payment structure does not acknowledge.

The labor story belongs here too. In 2023 pharmacy staff at CVS and Walgreens staged walkouts over understaffing, relentless workloads, and safety concerns. The protests did not invent the problem. They exposed it. By early 2026, after the Sycamore takeover, Walgreens was again cutting jobs, this time through layoffs and further rationalization. The crisis is not only one of buildings. It is also one of a workforce asked to carry clinical risk inside an increasingly brittle labor model.

The patient side of the story is just as revealing. Reporters covering rural and urban pharmacies alike found that staff members often knew customers by name, helped sort out mail-order problems, answered questions about insurance denials, and in some cases spotted signs of worsening illness. That is not sentimentality. It is a form of low-threshold vigilance. Community pharmacies are among the few places in health care where a person can ask a medically consequential question without an appointment fee, a portal password, or a three-week wait.

This is especially important in communities burdened by chronic disease. Pharmacists in Black and Hispanic neighborhoods often see disproportionate levels of diabetes, hypertension, asthma, and heart disease, not because pharmacists create these inequities but because they live downstream from them. When such a neighborhood loses a pharmacy, it loses one of the easiest points of contact with someone who understands the regimen, the refill pattern, the meter strips, the needles, the side effects, and the dull but indispensable discipline of staying on therapy.

There is also a dignity issue here that economists sometimes miss. A community pharmacy can preserve the ordinary honor of being known. That matters to older adults, to caregivers, to people embarrassed by illness, to patients who have spent enough time in bureaucratic systems that they no longer expect recognition. A familiar pharmacist does not solve structural injustice. Still, the difference between being processed and being known is one of the few differences that can be felt immediately in daily life.

When such stores close, the community loses more than inventory. It loses witness. The pharmacist who would have noticed that the bottle was never picked up, the technician who knows the delivery route, the owner who keeps an account open a few days longer for a struggling family, the person who answers the phone after the doctor's office has closed, all disappear into the abstraction of transferred files and redirected claims. The ledger balances somewhere. The life around the counter does not.

Buildings close. People also burn out. A country that normalizes both is moving backward.

Chapter Nine: The Great Society in Reverse

The disappearance of the community pharmacy is not only a business event. It is a civic test, and not a flattering one. It asks whether the United States still knows how to preserve local institutions once they stop delivering easy profit to concentrated systems that treat place as a spreadsheet variable.

The old American promise, however unevenly fulfilled, included a faith in local enterprise. A skilled immigrant or the child of one could imagine opening a shop, mastering a profession, serving a neighborhood, and building a life with some degree of independence. Pharmacy was one of the professions through which that promise once felt tangible. The store required training, discipline, licensing, and stamina, but it remained thinkable as a path into both service and ownership.

That path is far narrower now. To open a pharmacy in 2026 is not simply to secure a location and attract customers. It is to enter a market governed by network participation, reimbursement opacity, purchasing pressure, direct and indirect remuneration fees in some lines of business, accreditation burdens, data requirements, and competitors who may be tied to the very benefit managers deciding where patients can go. The aspiring independent pharmacist is not merely competing against a larger store.

He or she is entering a system in which the larger architecture may already have decided who gets fed.

There is something faintly un-American in that, not in a theatrical or flag-waving sense, but in the more serious sense that liberty in commerce becomes hollow when participation is formally allowed and functionally strangled. A country does not preserve entrepreneurship by praising it in speeches while allowing network design and vertical integration to make local survival structurally irrational.

The phrase Great Society belongs to Lyndon Johnson's era, but the underlying aspiration was wider than a legislative program. It carried the hope that public life could be organized so that opportunity widened rather than narrowed, and that essential goods would not be reserved to those already well positioned. One can disagree with the politics and still understand the civic moral of the phrase. In the pharmacy crisis, that moral has been reversed.

The system increasingly rewards scale, integration, and steerage while making local access contingent, especially in poorer and sicker communities.

It would be foolish to answer this reversal with nostalgia alone. The past had its own injustices. The old neighborhood order often excluded those it congratulated itself for serving. To defend the community pharmacy is not to ask for the return of every vanished feature of midcentury America. It is to insist that a society can preserve local access, professional independence, and neighborhood presence without reviving segregation, patronage, or provincialism.

That insistence also places a burden on professions adjacent to pharmacy, especially medicine. Physicians have often treated pharmacies as permanent background infrastructure, an extension of the prescribing act that simply exists to receive the order. The last few years should have cured us of that complacency. Prescribing is only half the act. A medication is not truly part of care until it reaches the patient in usable form, at the right price, in time, with explanation. If the pharmacy infrastructure collapses, physicians do not escape the consequences.

They inherit them in worse adherence, more complications, more emergency visits, and more therapeutic failure.

There is a real moral dilemma here for prescribers. A physician may believe, sincerely, that the local independent pharmacy deserves support and still know that the patient's plan punishes that loyalty with a higher copay or a denial. Sentiment is not a treatment. One cannot make a patient poorer in the name of civic virtue and call the result ethical. At the same time, a profession that never speaks for the survival of local pharmacies is abdicating a duty to the conditions of care.

The honest answer is not blind loyalty to one store or blind surrender to one platform. It is practical solidarity: understanding which patients need immediacy, which drugs can safely move by mail, which stores are fragile but vital, and which barriers are being imposed by benefit design rather than by medical necessity.

Advocacy has been slower than the crisis warrants, but it has not been nonexistent. Alabama enacted the Community Pharmacy Relief Act in April 2025, tying reimbursement for independent pharmacies to the state Medicaid methodology and restricting several PBM practices. Arkansas went further and became the first state to bar PBMs from owning or operating pharmacies, only to see the law hit by immediate lawsuits and then a federal preliminary injunction before it could take effect. A bipartisan coalition of 39 state and territory attorneys general called on Congress to prohibit PBM ownership of pharmacies altogether.

That sequence is instructive. State reform is hard not only because the industry is powerful, but because federal preemption doctrines and interstate-commerce arguments can turn each state statute into a prolonged court fight. In April 2026 the Sixth Circuit held that ERISA preempted Tennessee's any-willing-pharmacy restrictions for self-funded plans, a reminder that even after the Supreme Court's 2020 Rutledge decision, the legal ground remains uncertain and contested. The politics are angry. The architecture is stubborn.

The deeper question is whether the country is prepared to admit what kind of institution the pharmacy actually is. If it is merely retail, then the market's answer will be accepted and the closures will continue. If it is part of health care infrastructure, then the payment and regulatory system should reflect that reality. No society that genuinely believes access matters can leave essential local pharmacy entirely to the logic of whichever claims structure happens to dominate at the moment.

The pandemic made this contradiction embarrassing. It put pharmacists on a pedestal when the nation needed mass local delivery of care, then returned them to a payment model that treated their presence as incidental. The honor was real. So was the neglect that followed.

A mature society should find that sequence intolerable. If it does not, the future is easy to predict and hard to defend.

Chapter Ten: After the Drugstore

The future is unlikely to look like the old American drugstore, and wishing will not change that. The candy aisle, the photo counter, the wall of seasonal merchandise, and the assumption that every community can sustain a broad general-retail pharmacy format are all fading. The question is not whether change is coming. It is what kind of change we are willing to live with.

One possible future is already visible. Medicines for stable chronic conditions move increasingly through mail order, platform subscriptions, dose-packaging services, and same-day logistics networks. Amazon's 2026 plan to expand same-day pharmacy delivery to nearly 4,500 cities and towns is only the clearest symbol of a broader shift. PBM-owned mail and specialty channels will continue to absorb high-value prescriptions. For many patients, especially those who are digitally comfortable and taking predictable long-term therapies, this model can be efficient and genuinely helpful.

It would be dishonest to deny those advantages. Home delivery can be a gift to patients with mobility limits, busy caregivers, remote addresses, or complex medication schedules. Dose packaging can improve adherence. Price transparency tools can help some consumers find affordable options. A refill that appears at the door without a missed workday or long drive is not a trivial improvement.

Yet there is another possible future, darker and increasingly plausible, in which physical pharmacy does not vanish but thins into a sparse and uneven safety net. Affluent or dense markets retain multiple choices. Strategically desirable corridors keep stores. Specialty channels flourish. Everyone else is told that delivery, central fill, kiosks, or distant hubs are adequate substitutes for local presence. The healthiest and most digitally fluent adapt first. The elderly, the poor, the intermittently insured, the chronically ill, and the less mobile inherit the friction.

That future would be defended in the language of efficiency. It would still represent abandonment.

There is also a third path. In that version, the community pharmacy survives by becoming more explicitly what the country already uses it as, a local clinical access point that is paid not only for moving product but for providing health infrastructure. That would require reforms more serious than symbolic transparency rules.

That third path becomes more plausible once it is described in concrete rather than sentimental terms. Pharmacists can be paid directly for clinical work when policy allows it. Provider-status efforts are built on exactly that premise. A keystone pharmacy in a rural town or underserved neighborhood could also be supported through a base-presence model, something closer in spirit to the way the country already supports other thin-margin access points such as Rural Health Clinics and Federally Qualified Health Centers. The point would not be charity. It would be recognition that some facilities matter because they exist nearby, not merely because they maximize retail yield.

Such a model could include a reimbursement floor for dispensing essential drugs, enhanced payment for vaccinations and medication therapy management, transitional-care fees for post-discharge medication reconciliation, support for delivery in pharmacy deserts, and targeted grants or contracts for stores that serve as the last realistic pharmacy in a community.

In practical terms, three policy models stand out. One would tie minimum reimbursement for essential drugs to NADAC plus a workable dispensing margin, so that pharmacies are not routinely paid below acquisition cost. A second would create a keystone-pharmacy designation for the last realistic pharmacy in a rural county or medically underserved urban neighborhood, with base support analogous in spirit to the way Rural Health Clinics and Federally Qualified Health Centers are supported for maintaining access. A third would sharply limit, or in some states prohibit, PBM ownership of pharmacies and ban steering into affiliated channels on unfair terms. Each model has tradeoffs. The first costs money. The second requires clear eligibility rules. The third invites fierce legal and political resistance. But all three are real policy choices, not fantasies.

It would mean fair reimbursement floors, limits on abusive steering, protection for patient choice, targeted support for keystone pharmacies in underserved areas, recognition of pharmacists as clinical professionals when they are doing clinical work, and a willingness to treat some pharmacy locations the way we already treat other essential but difficult-to-finance services.

It may also mean a different store. The surviving pharmacy of the future might be smaller, more clinically focused, less dependent on selling detergent under fluorescent light, and more deeply integrated with local primary care, home health, and public health functions. The nostalgia model, preserving every feature of the old drugstore, is probably not financially realistic. The presence model, preserving the nearby pharmacist and the local counter while discarding the dead retail weight, has a better chance.

Nor would a modern community pharmacy need to reject technology in order to stay human. A serious local pharmacy can use e-prescribing, synchronized refills, text reminders, dose packaging, digital prior-authorization workflows, telepharmacy support, home delivery, and tight integration with local clinics. Amazon's advantage is not that technology exists. It is that technology has been paired with capital and scale. The local pharmacy can use many of the same tools. What it adds is proximity, continuity, and the possibility of being known.

That future would also require intellectual honesty from reformers. PBMs are not the whole story. Online competition matters. Front-end retail decline matters. Labor shortages matter. Corporate overexpansion mattered. In some cities, chains really did build more stores than the market or the community needed. A credible defense of community pharmacy has to acknowledge all of that. Otherwise reform collapses into slogan.

Still, one should not let complexity become paralysis. The fact that many forces have contributed to the crisis does not absolve the most powerful actors of responsibility. A system in which three PBMs control most claims, own affiliated dispensing channels, and help determine which pharmacies live or die is not a naturally occurring ecosystem. It is a human design. So is a world in which a pharmacist can lose money dispensing insulin to a patient who urgently needs it.

The future of pharmacy will therefore be decided not only by technology or consumer habit, but by what we are willing to call unacceptable. If it is acceptable that a minority neighborhood lose its last nearby pharmacy while a platform promises two-day delivery, then the future is already written. If it is acceptable that rural patients be routed through distant fulfillment channels because their local store no longer fits the margin model, then the future is already written.

If, on the other hand, we decide that local access to medicines is part of the country's basic civic equipment, then other outcomes remain possible.

Every era inherits institutions that no longer fit neatly inside the categories used to pay for them. The pharmacy is one of those institutions now. It is too clinical to be understood as ordinary retail and too commercially burdened to function like a purely public service. The task ahead is to resolve that contradiction honestly.

Not with nostalgia. Not with surrender. With policy, payment, and a decision that local pharmacy access is either part of the country's civic equipment or it is not.

Epilogue

A country rarely notices the full meaning of a local institution while it still seems ordinary.

Ordinary things disappear quietly. They blend into errands and routines for so long that people stop seeing them clearly. The pharmacy occupied that category for a very long time. It was there when the doctor's office was closed, when the child had a fever, when the bus was late, when the blood sugar strips ran low, when the vaccine finally arrived, when someone needed to ask a medically serious question without scheduling an appointment and waiting three weeks.

It may not occupy that category much longer.

What is being lost, if present trends continue, is not simply one retail format among many. It is a certain kind of presence. Modern systems are very good at scale, routing, central fill, and optimization. They are less good at honoring proximity. Yet proximity is one of the quiet foundations of civilized care. To have medicines somewhere in the system is not the same as having them within reach. To have a pharmacist available by phone is not always the same as having one in the neighborhood. To have theoretical access is not the same as having a door nearby with lights on.

That is why this argument is not nostalgic at its core. The community pharmacy is worth saving not because it belongs to a vanished America, but because it remains one of the few places where medicine is still made local. If we allow that function to be hollowed out in the name of an efficiency that leaves millions farther from care, the loss will not be sentimental. It will be practical, civic, and expensive in the deepest sense of the word.

The consequences are not theoretical. They show up as delayed antibiotics, missed insulin, broken discharge plans, more avoidable emergency visits, worse adherence, and wider inequality between communities that still have options and communities that do not. The system will describe this as rationalization. Many patients will experience it as abandonment.

The surprise is not that so many pharmacies are under strain. The surprise is that they lasted this long under rules so poorly matched to what we ask them to be.

The rest is choice.

Appendix. A Note for Prescribers

Prescribers sit in an awkward moral position in this story. We send the prescription, but we do not control the geography into which it lands. We may know the patient well in diagnostic terms and still know far too little about whether the medication will be affordable, stocked, deliverable, or realistically obtainable before the next dose is due.

That should trouble us more than it usually does.

A prescription is not fulfilled when the order leaves the electronic medical record. It is fulfilled when the patient obtains the medication in time, understands how to use it, and can continue using it without being defeated by cost or logistics. That means the work of the prescriber and the work of the pharmacist are linked more tightly than our professional habits sometimes admit.

The first ethical duty is to the patient in front of us. If a health plan covers a medication only through mail order, or if a neighborhood pharmacy cannot obtain the drug at an affordable price, the clinician cannot answer with romanticism alone. One does not prove loyalty to the independent store by imposing higher cost or dangerous delay on a sick person. The patient is not a symbolic instrument in a larger policy argument.

The second duty, however, is not surrender. Physicians and other prescribers should understand that the pharmacy market is not a neutral consumer arena. It is part of the operating environment of care. If a community loses its last accessible pharmacy, that loss returns to the clinic and the hospital as failed adherence, avoidable complications, brittle discharges, and worsening disease.

This is where practical solidarity matters.

Acute medications, antibiotics, rescue inhalers, post-procedure analgesics, time-sensitive psychiatric changes, and drugs needed the same day after discharge should, whenever possible, be sent where the patient can realistically obtain them that day. Stable maintenance medications can sometimes move safely through ninety-day or mail-order channels. Those two situations are not the same. A clinician who treats them as interchangeable is not practicing efficiency. He is refusing to notice time.

Prescribers can also afford to be more curious than many of us have been. Which local pharmacies deliver? Which ones are reliable with prior authorizations? Which ones are fragile but indispensable to the neighborhood? Which chains have cut staffing so severely that delays are now routine? Which patients in a given practice are least able to absorb a forced shift to mail order? These are not administrative trivia. They are part of the real treatment plan.

There is another duty, quieter but no less important. Clinicians should stop speaking of pharmacies as though they were fungible endpoints in a software workflow. Every experienced doctor knows that some pharmacists catch errors more readily, call with better judgment, solve insurance problems with more patience, or take more trouble to explain a regimen to a bewildered family. The relationship need not become clubby to matter. Mutual respect between prescriber and pharmacist still improves care.

The final duty is political in the broad sense of the word. If physicians believe that continuity, adherence, and neighborhood access matter, then we should be willing to support payment and regulatory reforms that protect keystone pharmacies in underserved areas and restrain predatory steering. It is easy to complain when a medication goes unfilled. It is harder, but more honest, to defend the institutions that make filling possible.

No clinician can save the local pharmacy alone. Yet no clinician is neutral in its disappearance either. We write into the system every day. We should at least know what the system is doing to the last person who touches the medicine before it reaches the patient.

About the Author

Timothy Lesaca, MD, is a psychiatrist in full-time practice in Pittsburgh, Pennsylvania. Double board-certified in General Psychiatry and Child and Adolescent Psychiatry, he has spent more than four decades working at the intersection of clinical care, institutional systems, and the ethics of medical practice.

A graduate of the West Virginia University School of Medicine, where he also completed residency and fellowship training, Dr. Lesaca has worked across outpatient, inpatient, and community mental health settings. His writing examines how health-care structures, policy decisions, and professional cultures shape the lives of patients, physicians, and communities.

References

American Pharmacists Association. History of pharmacy and public materials on the development of pharmacy education and practice in the United States.

Britannica. "Apothecary." Updated 2026.

Britannica. "Pharmacy." Updated March 28, 2026.

Centers for Disease Control and Prevention. Federal Retail Pharmacy Program archived program materials, including participation totals and dose administration data.

El Kalach, R., et al. "Federal Retail Pharmacy Program Contributions to Bivalent COVID-19 Vaccination in the United States." Morbidity and Mortality Weekly Report 73, no. 13 (2024).

Guadamuz, Jenny S., et al. "Access to Pharmacies and Pharmacy Services in New York City, Los Angeles, Chicago, and Houston, 2015 to 2020." Journal of the American Pharmacists Association 61, no. 6 (2021).

Guadamuz, Jenny S., et al. "Pharmacy Deserts in the Thirty Most Populous U.S. Cities." Health Affairs 40, no. 8 (2021).

Guadamuz, Jenny S., and colleagues. "More U.S. Pharmacies Closed Than Opened in 2018 to 2021." Health Affairs 43, no. 12 (2024).

Mathis, W. S., et al. "Vulnerability Index Approach to Identify Pharmacy Deserts and Keystone Pharmacies in the United States." JAMA Network Open 8, no. 3 (2025).

JAMA Health Forum. Study of openings and closures among chain pharmacies in the United States, 2010 to 2023. Published 2025.

CVS Health Corporation. Annual Report on Form 10-K for fiscal year 2024.

Walgreens Boots Alliance. Annual Report on Form 10-K for fiscal year 2024.

Federal Trade Commission. "Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies." Interim staff report, July 2024.

Federal Trade Commission. Second interim staff report on pharmacy benefit managers and affiliated specialty pharmacies, January 14, 2025.

KFF. "What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation." February 9, 2026.

Reuters. "Rite Aid files for second bankruptcy in two years." May 5, 2025.

Reuters. "Court approves fire sale of most of Rite Aid's pharmacy assets." May 21, 2025.

Reuters. "Walgreens to be taken private by Sycamore in $10 billion deal." March 7, 2025.

Reuters. "Walgreens names retail veteran Mike Motz as CEO after Sycamore takes chain private." August 28, 2025.

Reuters. "Walgreens cuts workforce after private equity buyout, Bloomberg News reports." February 19, 2026.

Reuters. "Amazon Pharmacy to expand same-day delivery to about 4,500 U.S. cities and towns." February 11, 2026.

National Association of Attorneys General. "State and Territory Attorneys General Call on Congress to Prohibit Pharmacy Benefit Managers from Owning or Operating Pharmacies." April 14, 2025.

Governor Kay Ivey and Alabama Pharmacy Association. Materials on the Community Pharmacy Relief Act, signed April 15, 2025.

Associated Press. "Alabama approves regulations on pharmacy benefit managers in order to help small pharmacies." April 8, 2025.

Reuters. "CVS, Express Scripts sue to block Arkansas law barring PBM ownership of pharmacies." May 29, 2025.

Associated Press. "Federal judge blocks Arkansas law barring pharmacy benefit managers from owning pharmacies in state." July 28, 2025.

Rutledge v. Pharmaceutical Care Management Association, 592 U.S. ___ (2020).

Axios. "States' efforts to rein in PBMs hit a legal roadblock." April 15, 2026.

USC Today. "One-third of all neighborhoods in the largest U.S. cities have been pharmacy deserts." May 3, 2021.

WTTW News. "Some Neighborhoods on South and West Sides See Increasing 'Pharmacy Deserts'." August 9, 2022.

Associated Press. "Rural pharmacies fill a health care gap in the U.S. Owners are struggling to stay open." June 7, 2024.

Associated Press. "Forced to sell medications at a loss, rural Texas pharmacies struggle to survive." March 27, 2026.

American Journal of Pharmaceutical Education. Articles on the Flexner era and pharmacy education reform.

National Community Pharmacists Association. NCPA Digest and related materials on the economic condition of independent community pharmacies.

Academy of Managed Care Pharmacy. "Provider Status for Pharmacists." Public policy materials.

Rural Health Information Hub. Rural Health Clinics overview and materials on sustaining access in underserved communities.